Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

Senator Christopher Cabaldon (D-Yolo) announced Senate District Three’s 2025 Woman of the Year — Carol Whichard, who was ...

SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, today announced that it has dosed the first patient in the ...

Researchers at Kumamoto University have successfully executed a practical trial of a new genome-editing technique that allows ...

We believe that the Propel XFrame solution is the answer to our data center customers’ most pressing needs. The accelerating ...

QRL-101-03 (NCT06532396) is a randomized, double-blind, placebo-controlled, multiple-ascending dose clinical trial evaluating the safety, tolerability, and PK of QRL-101 in up to 60 healthy ...

BMO Capital Markets initiated coverage on Dyne Therapeutics (DYN, Financials) with an Outperform rating and a $50 price ...

A viral video on TikTok claims that Kenyan president William Ruto has appointed opposition leader Raila Odinga as the new prime cabinet secretary.

The self-fusing silicone tape market share analysis is poised for significant expansion, expected to surpass USD 30,870.8 ...

CommScope announced the launch of its Propel XFrame™ solution as the latest addition to the Propel™ portfolio of ...

Compact floor-mounted fiber frame solution simplifies and accelerates management in high-density data centres ...